CAR-T cells targeting intracellular proteins are expected to greatly expand the types of cancers that can be treated

CAR-T cell therapy has shown significant efficacy in the treatment of hematological cancers, but it still faces multiple challenges in the treatment of solid tumors

Most of the proteins that drive tumorigenesis are intracellular proteins

In this study, the research team used multi-omics techniques to analyze 7608 polypeptides presented by MHC on the surface of neuroblastoma and found that a polypeptide produced by the PHOX2B gene is tumor-specific

However, since the PHOX2B polypeptide presented to the cell surface by MHC is relatively short, antibodies that can specifically bind to it but do not bind to normal cells are very rare

In animal models, this CAR-T cell therapy can significantly reduce the size of neuroblastoma transplanted into mice

Reference materials:

[1] Myrio Therapeutics data published in Nature: unlocking new targets for antibody-based therapies.

[2] CHOP researchers develop a new class of CAR-T cells that target previously untargetable cancer drivers.

(The original text has been deleted)